

Vaccine Clinic Resource for Immunizers
***Disclaimer:** this Quick Reference is not intended to replace other product specific vaccine references. The document is intended as a quick reference for frequently referred to information. Please refer to the product monograph and vaccine specific resources for all current and complete information.*

Title:	<p>Meningococcal (Men-C-ACYW) Vaccine Quick Reference Guide</p> <p><i>This guide provides information for the Men-C-ACYW vaccines available in Manitoba to support the Meningococcal Targeted Catch-up Campaign for those born on or after January 1, 2020.</i></p>
Effective Date:	February 14, 2024
Approver:	Final

Meningococcal Vaccine Resources:

Fact sheets

<https://www.manitoba.ca/health/publichealth/factsheets/mcq.v.pdf>

Product Monographs

- [Meningococcal Conjugate Quadrivalent Vaccine – Menactra® Product Monograph](#)
- [Meningococcal Conjugate Quadrivalent Vaccine - Nimenrix® Product Monograph](#)

Eligibility Criteria

For the most up to date information on eligibility criteria refer to <https://www.manitoba.ca/health/publichealth/cdc/vaccineeligibility.html>

Manitoba Immunization Schedule:

<https://www.manitoba.ca/health/publichealth/cdc/div/schedules.html>

Canadian Immunization Guide:

For additional guidance on contraindications, precautions and special populations refer to the meningococcal vaccine specific section:

<https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines.html>

Meningococcal Vaccine - Men-C-ACYW (Quadrivalent)			
Product	Storage and Handling	Eligibility Criteria	Recommendations for Use
<p>Menactra®</p> <p>Meningococcal (Groups A, C, Y and W) Polysaccharide Diphtheria Toxoid Conjugate Vaccine</p> <p>Format: Single and 5/per box 0.5ml vials</p>	<p>Storage: Refrigerated 2° to 8°C until expiry date on label.</p> <p>Do NOT freeze.</p> <p>Handling: Reconstitution NOT required</p> <p>Shake the vaccine well until a uniform, clear to slightly turbid liquid results.</p>	<p><u>12-month program</u></p> <ul style="list-style-type: none"> Individuals born on or after January 1, 2020, are eligible to receive a dose regardless of previous Men-C-C immunization history if they are at least 12 months of age but < 10 years of age. ^o Individuals born between Jan 1, 2008, and December 31, 2019, are eligible to receive a dose IF they never received a dose of Men-C-C vaccine as part of the 12-month program AND are <10 years old. <p><u>School-based immunization program</u></p> <ul style="list-style-type: none"> Individuals born on or after January 1, 2008, are eligible to receive a dose at ≥ 10 years of age routinely offered in Grade 6 regardless of Men-C-C or Men C-ACYW immunization history. 	<p>Regimen: 2 doses 12-23 months of age* 1 dose 24 months and up*</p> <p>NOT recommended for children who have not completed their pneumococcal conjugate immunizations**</p> <p>Dosage: 0.5 ml Route: IM</p> <p>Interval: 2 dose series requires a minimum 3 month interval <i>*Those with certain high-risk medical conditions may require additional doses see Manitoba Health eligibility criteria for a complete list and refer to the Canadian Immunization guide for dose requirements and intervals.</i></p>
Product is latex and preservative/thimerosal free. Potential Allergens: Diphtheria toxoid carrier protein Other Ingredients: Sodium chloride, sodium phosphate dibasic anhydrous, sodium phosphate monobasic			
Product	Storage and Handling	Eligibility Criteria	Recommendations for Use
<p>Nimenrix®</p> <p>Meningococcal polysaccharide groups A, C, Y and W conjugate vaccine</p> <p>Format: Single dose vial of sterile lyophilized white powder or cake; diluent presented in a pre-filled syringe (0.5 ml)</p> <p>Single or 10/box vials</p>	<p>Storage: Refrigerated 2° to 8°C until expiry date on label.</p> <p>Do NOT freeze. Protect from light.</p> <p>Handling: <u>Reconstitution required</u> Add entire contents of the pre-filled syringe of diluent to the vial containing the powder. Reconstituted vaccine is a clear, colorless solution. Promptly use the vaccine after reconstitution.</p>	<p><u>12-month program</u></p> <ul style="list-style-type: none"> Individuals born on or after January 1, 2020, are eligible to receive a dose regardless of previous Men-C-C immunization history if they are at least 12 months of age but <10 years of age. ^o Individuals born between Jan 1, 2008, and December 31, 2019, are eligible to receive a dose IF they never received a dose of Men-C-C vaccine as part of the 12-month program AND are < 10 years old. <p><u>School-based immunization program</u></p> <ul style="list-style-type: none"> Individuals born on or after January 1, 2008, are eligible to receive a dose at ≥ 10 years of age routinely offered in Grade 6 regardless of Men-C-C or Men C-ACYW immunization history. 	<p>Regimen: 1 dose*</p> <p>Dosage: 0.5 ml Route: IM</p> <p>Interval: <i>*Those with certain high-risk medical conditions may require additional doses - see Manitoba Health eligibility criteria for a complete list and refer to the Canadian Immunization guide for dose requirements and intervals.</i></p>
Product is latex and preservative/thimerosal free. Potential Allergens: Tetanus toxoid carrier protein Other Ingredients: Sucrose, Trometamol, Sodium chloride			

** For children that have not completed their pneumococcal conjugate immunization series, Nimenrix® should be offered due to the potential of Menactra® to decrease the effectiveness of the initial immune response to the pneumococcal conjugate vaccine. For children that have completed their pneumococcal series, they may receive Nimenrix®; or they may receive Menactra® if it has been at least 4 weeks since completing the pneumococcal series.

^oNote: For those previously immunized with Men-C-C, a minimum interval of 4 weeks is recommended prior to receiving a dose of Men-C-ACYW.